Core Viewpoint - The medical sector is showing signs of recovery in 2026, driven by policy clarity and the realization of innovative outcomes, leading to increased investment interest in medical ETFs [1][19]. Group 1: Current Core Logic and Positive Factors in the Medical Sector - The transition from "selling expectations" to "performance realization" is evident, with domestic medical device innovations gaining global recognition, thus becoming a new growth engine for the industry [3][21]. - The medical sector is experiencing a high proportion of companies meeting or exceeding their 2025 performance forecasts, indicating a favorable industry outlook [3][21]. - The recent surge in AI medical technologies is not just speculative but demonstrates clear cost-reduction and efficiency-enhancing capabilities in hospital operations and drug development [4][23]. Group 2: Policy Environment Changes - The policy environment has shifted from a "speed over quality" approach to one of "value co-creation," with recent signals indicating a more favorable stance on centralized procurement and medical insurance negotiations [6][24]. - Optimizations in the approval process for innovative medical devices and continuous improvements in procurement rules are expected to enhance the competitive landscape and restore profitability for companies [8][26]. - The introduction of a market exclusivity period in the revised Drug Administration Law is expected to boost long-term investment confidence in pharmaceutical R&D [9][27]. Group 3: Financial Support for Medical Equipment Updates - The national "two new" policy, focusing on large-scale equipment updates and consumer goods replacement, has allocated 62.5 billion yuan in special bonds to support medical equipment upgrades, benefiting listed companies in the medical device sector [10][28]. - There is a significant demand for replacing outdated medical equipment in domestic healthcare institutions, coupled with policies favoring domestic alternatives, leading to increased orders and market share for leading companies in imaging, surgical robots, and in-vitro diagnostics [10][28]. Group 4: Reasons for Recent Fund Inflows into Medical ETF (512170) - The medical ETF (512170) has seen substantial inflows, with a single-day capital increase of 499 million yuan on January 28, 2026, and a total of 1.8 billion yuan over nine consecutive trading days, reflecting a shift in market sentiment towards value recovery [1][19][14]. - The medical ETF is currently one of the largest medical-themed ETFs in A-shares, with a market size exceeding 26 billion yuan, driven by high cost-effectiveness and a consensus on bottom valuations [14][32]. - The ETF closely tracks the CSI Medical Index, with significant allocations in medical devices (53.17%) and medical services, making it an attractive option for both institutional and retail investors [14][32][34].

Market Performance - The Shanghai Composite Index rose by 0.16% to 4157.98 points, while the Shenzhen Component fell by 0.3% and the ChiNext Index dropped by 0.57%[1] - The Hong Kong Hang Seng Index increased by 0.51% to 27968.09 points, with the Hang Seng Technology Index declining by 1% and the Hang Seng China Enterprises Index rising by 0.42%[1] - The total market turnover in Hong Kong was 3319.942 million HKD[1] Currency and Economic Relations - The U.S. Treasury Department labeled the Chinese yuan as "severely undervalued" and urged China to allow timely appreciation of its currency[12] - A survey by Goldman Sachs indicated that the majority of investors expect the yuan to appreciate against the U.S. dollar this year[8] Corporate Earnings - Apple reported a record quarterly revenue of 143.8 billion USD, exceeding Wall Street expectations, with a 38% increase in revenue from China[12] - The anticipated net profit for Sunny Optical Technology is expected to increase by 70% to 75%, reaching approximately 4.589 to 4.724 billion RMB[14] Bilateral Agreements - China and the UK reached 11 positive outcomes during Prime Minister Keir Starmer's visit, including the establishment of a yuan clearing bank in the UK and a reduction in whisky import tariffs from 10% to 5%[12]

Group 1: Market Overview - The market is experiencing a volatile trading environment with a focus on dividend and consumption sectors, while the hard technology sector is underperforming [5][10] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the ChiNext Index fell by 0.57% to 3304.51 [5][8] - The trading volume exceeded 32 trillion yuan, indicating a high trading sentiment, but the market continues to show signs of structural differentiation [10] Group 2: Industry Dynamics - Meta's advertising revenue reached $58.137 billion in Q4 2025, a 24% year-on-year increase, with total revenue for the quarter at $59.893 billion [29][30] - UBI Research forecasts a 64% increase in OLED display shipments in 2025, reaching 3.2 million units, driven by higher acceptance and profitability in the sector [31] - Omdia predicts a decline in AMOLED panel shipments for smartphones in 2026, estimating a drop to 810 million units due to rising memory costs and supply shortages [33] Group 3: Company Updates - Tigermed (300347.SZ) expects 2025 revenue between 6.66 billion and 7.68 billion yuan, with a net profit forecasted to grow by 105% to 204% [37][38] - Chunxue Food (605567.SH) anticipates a staggering 340.90% to 426.63% increase in net profit for 2025, driven by market expansion and cost reduction efforts [39][40] - Qingdao Bank (002948.SZ) reported a 7.97% increase in revenue for 2025, with net profit reaching 5.188 billion yuan, reflecting steady growth in assets and loans [43][44]

业内人士认为，赛道基金走红，主要原因是其优异的业绩表现。多只有色金属赛道ETF今年涨幅超 30%，部分黄金股ETF更是涨超50%，远超市场平均水平。高收益诱惑下，投资者越涨越买，越买越推 升上涨，形成了资金抱团的循环。 少有常胜赛道 近期，赛道型基金进入聚光灯下。有色金属、AI等赛道型基金净值一路飙升，点燃投资者热情，大量 资金争相涌入。无论是主动还是被动产品，赛道型基金的吸金势头均更胜一筹。 赛道型基金的业绩锐度难免让人心动，但热闹之下，暗流涌动的风险也不容忽视。业内人士提示，应警 惕赛道型基金的"双刃剑"效应。 赛道型产品强劲吸金 区别于撒网式选股的全市场基金，赛道型基金剑指单一行业或主题。而在近期赛道型基金强势行情催化 下，有大量投资者蜂拥而至。 主动权益基金里，赛道型选手们上演大翻盘。2025年四季报显示，不少此前规模不足1亿元的小微基 金，靠着精准卡位高景气赛道，实现规模数十倍的暴增。 例如，某聚焦半导体产业的基金产品，首募不到1亿元，短短一个季度，其规模飙升至超90亿元，增长 超90倍。一家基金公司旗下的医药生物主题基金同样规模大增，从2025年三季度末的0.39亿元增至2025 年四季度末的8亿 ...

随着上市公司2025年业绩预告进入密集披露期，多家科创板企业年度业绩"答卷"也提前揭晓。 Wind数据显示，截至1月29日19时30分，超260家科创板公司公布2025年业绩预告，从披露情况来看， 报喜公司（包括预增、扭亏、略增）数量达105家，占比约四成，还有超50家公司预计同比减亏。 业内人士认为，科创板紧密连接国家科技创新战略，聚焦人工智能、生物医药等前沿领域，其制度创新 吸引优质企业上市，并不断吸引"耐心资本"入场。目前随着上市公司年报业绩预告进入密集披露阶段， 市场驱动逻辑正转向对业绩增长与盈利改善的验证层面。 多家企业预计净利润增幅超100% 具体来看，截至1月29日19时30分，超260家科创板公司公布2025年业绩预告。其中，62家预增、34家扭 亏、9家略增、51家减亏。此外，还有8家科创板公司发布业绩快报，其中6家预计净利润同比增长。 臻镭科技称，受国内特种行业周期影响，特种集成电路行业下游客户的产品需求有所增加，同时公司积 极把握卫星通信领域市场机遇，市场拓展节奏稳步加快，项目交付能力显著提升，整体推动了公司销售 收入实现高速增长。 新签订单屡创新高 值得一提的是，订单增长成为部分科创板 ...

Core Insights - The article highlights the early disclosure of annual performance forecasts by over 260 companies on the STAR Market, with approximately 40% of them reporting positive growth or recovery in profits [1] - The focus is on the connection between the STAR Market and national technology innovation strategies, particularly in sectors like artificial intelligence and biomedicine, attracting quality companies and long-term capital [1] Group 1: Performance Forecasts - As of January 29, over 260 STAR Market companies have disclosed their 2025 performance forecasts, with 62 companies expecting profit increases, 34 companies turning losses into profits, and 51 companies reducing losses [1] - Among the companies forecasting profit increases, over 30 are expected to see net profit growth exceeding 100%, while 26 companies anticipate growth between 50% and 100% [2] Group 2: Industry Trends - The companies expecting profit growth are primarily in hardware, semiconductors, and biomedicine sectors, benefiting from recovering industry demand and breakthroughs in products [2] - Shanghai Yizhong expects the highest net profit increase of 760.18%, driven by its core product being included in the national medical insurance directory, significantly boosting market access and patient numbers [2] Group 3: Order Growth - Order growth is identified as a key driver for performance increases among some STAR Market companies, with significant new orders contributing to revenue growth [2] - Chip Origin Co. anticipates a narrowing of net losses, supported by record-high new orders, with total new orders for 2025 reaching 5.96 billion, a year-on-year increase of 103.41% [4] - Companies like Aifute have also reported substantial new orders, indicating positive future impacts on their performance [4]

Core Insights - The independent director system for listed companies in China is undergoing a significant transformation, with the introduction of the "Management Measures for Independent Directors of Listed Companies" in August 2023, which allows investor protection agencies to publicly solicit shareholder rights and nominate independent directors [1][2] Group 1: Key Developments - The new regulations aim to enhance the representation of minority shareholders, particularly those who have been historically silent [1] - The China Securities Investor Services Center has successfully implemented this system in five cases over a year and a half, covering various ownership structures and regions [1][4] - The evolution of the nomination process has shown a clear trend towards "joint action" and an expansion of the backgrounds of independent directors from industry experience to accounting expertise [2][4] Group 2: Challenges and Responses - Despite a high approval rate of over 99% for the shareholder meetings regarding the nominated independent directors, the actual participation of investors in the solicitation process remains limited, highlighting the ongoing issue of minority shareholders' "free-riding" mentality [2][10] - The operational challenges faced by the China Securities Investor Services Center include the difficulty in uniting shareholders who hold more than 1% of shares to exercise their voting rights [9][10] - Recommendations have been made to improve investor participation through education and the establishment of efficient online authorization systems [10] Group 3: Governance Implications - The involvement of the China Securities Investor Services Center in nominating independent directors represents a shift from external oversight to internal participation in corporate governance [7][8] - The selection of independent directors has focused on their professional qualifications and experience, which is expected to enhance the effectiveness of corporate governance [5][8] - The successful nomination of independent directors is seen as a step towards empowering minority shareholders and improving the balance of power within corporate boards [7][8]

本报记者 毛艺融 "国家队基金"（如中央汇金、社保基金、地方产业母基金）通常率先布局战略性新兴产业，承担风险定 价与市场信心塑造等功能，例如去年11月份，A股公司赛力斯集团股份有限公司H股上市时，重庆产业 投资母基金现身其基石投资者名单。今年1月份，江西国控私募基金管理有限公司出现在了上海龙旗科 技股份有限公司的H股基石投资者名单里。 数据显示，截至1月29日，"A+H"股累计已达167家。瑞银集团中国区总裁及瑞银证券董事长胡知鸷向 《证券日报》记者表示，从2024年四季度开始，"A+H"模式迎来新一轮扩容潮。2025年更多A股公司成 功登陆港股，尤其是一些细分行业龙头、大市值的公司接连在港股上市。此外，还有很多A股公司启动 了"A+H"的计划与项目。 国际投资者加码 数据显示，自去年以来，瑞银环球资产管理（新加坡）有限公司、阿布达比投资局、未来资产证券有限 公司、施罗德集团等国际长线资金出现在港股IPO的基石投资名单中。 今年1月份以来，中东主权财富基金、欧洲家族办公室等国际长线资金频频现身，主动将资金锁定6至12 个月。例如，MiniMax（稀宇科技）引入了阿布扎比投资局、Eastspring（瀚亚投资） ...

Core Viewpoint - As of January 20, 2026, the number of shareholders for Furuimei Medical (300049) is reported to be 22,242 [1] Company Information - Furuimei Medical has engaged with investors through an interactive platform, indicating a level of transparency and communication with its shareholder base [1] - The company is actively monitoring its shareholder count, which may reflect its growth and investor interest [1]

Core Viewpoint - The A-share market is experiencing volatility with a divergence between large-cap and small-cap stocks, indicating a cautious sentiment among investors as they prepare for the upcoming holiday season [4][7]. Market Performance - The Shanghai Composite Index showed a slight increase of 0.16%, while the overall market saw 1,801 stocks rise and 39 stocks hit the daily limit up, contrasting with 36 stocks that hit the limit down [5][6]. - The trading volume in both markets reached 0.23 trillion yuan, reflecting an 8.92% increase, suggesting heightened market activity and significant trading disputes between bulls and bears [7]. Capital Flow - There is a notable outflow of institutional funds, while retail investors are showing a net inflow, indicating a shift in investment strategies. Institutions are moving away from high-valuation growth sectors like semiconductors and new energy, while increasing positions in defensive sectors such as liquor, precious metals, and high-dividend financial blue chips [8]. - Retail investors are generally adopting a wait-and-see approach, with many choosing to hold cash during the holiday, while a small number are following trends in liquor and precious metals [8]. Investor Sentiment - The sentiment among retail investors is cautious, with 36.45% increasing their positions, 18.28% reducing them, and 36.45% remaining inactive [13]. - A significant portion of investors (45.95%) reported being in a position of profit, while 37.16% are facing losses of up to 20% [19].